**Deals and M&A Biotech and Medtech**

**Facts & Figures**

**2017**

**889 deals worldwide**

- Total worth $79 Bn
- Average deal value $410 M
- 36% of deals in oncology
- 42% of deals are licensing agreements
- 10% in neurology
- 21% for small molecules
- 38% of deals for biologics
- 36% antibodies
- 15% protein / peptide
- 8% cell therapy
- 8% biomarker

**American companies are present in 9 out of 10 top deals**

**Top 3 deals worldwide**

1. $8.5 Bn
   - Regeneron Pharmaceuticals, Oncology
2. $2.85 Bn
   - AbbVie, Pharmacy, Autoimmune
3. $2.83 Bn
   - Biogen, Alzheimer’s

**Top 3 deals with French Biotech**

1. $460 M
   - Sanofi, Oncology
2. $299 M
   - Roche, Hematology
3. $257 M
   - AstraZeneca, Oncology

*Sources: BioCentury (January 2018); France Biotech*

**Facts & Figures**

**2017**

**112 M&A operations worldwide**

- 90 acquisitions
- 22 mergers
- Main therapeutic areas of companies
  - 25% in oncology
  - 11% infectious diseases
  - 7% in neurology
  - 6% metabolism
- 32% for biologics
- 26% for small molecules

**Stage of target company at signing**

- 22% antibodies
- 17% protein / peptide
- 17% vaccine

**Top 3 M&A operations**

1. $30 Bn
   - Actelion, bought by Johnson & Johnson
2. $11.9 Bn
   - Elanco, bought by Eli Lilly
3. $7.2 Bn
   - Patheon, bought by Thermo Fisher Scientific

*Sources: BioCentury (January 2018); France Biotech*